Comments
Loading...

Context Therapeutics

CNTXNASDAQ
Logo brought to you by Benzinga Data
$1.15
0.1717.35%
At close: -
$1.14
-0.01-0.87%
After Hours: 3:05 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$10.00
Lowest Price Target1
$4.50
Consensus Price Target1
$7.90

Context Therapeutics (NASDAQ:CNTX) Stock, Analyst Ratings, Price Targets, Forecasts

Context Therapeutics Inc has a consensus price target of $7.9 based on the ratings of 5 analysts. The high is $10 issued by Maxim Group on May 9, 2024. The low is $4.5 issued by Piper Sandler on May 16, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital, HC Wainwright & Co., and HC Wainwright & Co. on November 25, 2024, September 23, 2024, and September 16, 2024, respectively. With an average price target of $7 between D. Boral Capital, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 514.04% upside for Context Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jul
2
Sep
1
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

D. Boral Capital
HC Wainwright & Co.
Piper Sandler
Maxim Group
ThinkEquity

1calculated from analyst ratings

Analyst Ratings for Context Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Context Therapeutics (CNTX) stock?

A

The latest price target for Context Therapeutics (NASDAQ:CNTX) was reported by D. Boral Capital on November 25, 2024. The analyst firm set a price target for $9.00 expecting CNTX to rise to within 12 months (a possible 689.47% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Context Therapeutics (CNTX)?

A

The latest analyst rating for Context Therapeutics (NASDAQ:CNTX) was provided by D. Boral Capital, and Context Therapeutics initiated their buy rating.

Q

When was the last upgrade for Context Therapeutics (CNTX)?

A

The last upgrade for Context Therapeutics Inc happened on November 1, 2023 when HC Wainwright & Co. raised their price target to $5. HC Wainwright & Co. previously had a neutral for Context Therapeutics Inc.

Q

When was the last downgrade for Context Therapeutics (CNTX)?

A

The last downgrade for Context Therapeutics Inc happened on March 23, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Context Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Context Therapeutics (CNTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Context Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Context Therapeutics was filed on November 25, 2024 so you should expect the next rating to be made available sometime around November 25, 2025.

Q

Is the Analyst Rating Context Therapeutics (CNTX) correct?

A

While ratings are subjective and will change, the latest Context Therapeutics (CNTX) rating was a initiated with a price target of $0.00 to $9.00. The current price Context Therapeutics (CNTX) is trading at is $1.14, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch